Board Member
Exagen Inc. (XGN)Equibles does not estimate personal net worth.
Get an email with a short summary when Exagen Inc. publishes a filing, an earnings call transcript or a press release.
Get XGN alertsFrank Stokes is recorded as Board Member at Exagen Inc. (XGN) and CFO at Castle Biosciences Inc (CSTL). The newest filing on record that lists Frank Stokes as Board Member at Exagen Inc. (XGN) is dated April 27, 2026. The newest filing on record that lists Frank Stokes as CFO at Castle Biosciences Inc (CSTL) is dated April 8, 2026. The proxy statement of Castle Biosciences Inc reports total compensation of $880,250 for Frank Stokes in fiscal 2023, including a base salary of $488,800. Disclosed compensation is on record for 6 fiscal years. Frank Stokes has spoken on 26 earnings calls and 3 other investor events across 1 company, most recently for Castle Biosciences Inc on September 15, 2026. Castle Biosciences Inc is classified in the Diagnostics & Research industry within the Healthcare sector. Exagen Inc. is classified in the Diagnostics & Research industry within the Healthcare sector. Other leadership on record at Castle Biosciences Inc includes Derek Maetzold (CEO and Board Member), Kristen M. Oelschlager (COO), Kimberlee Caple (Board Member) and 2 others.
“So I think that we had certainly a good quarter. I think our two main revenue drivers, our melanoma test, our tissue cipher test, we saw good progress there. I think on tissue cipher, I would encourage sort of looking at a four-quarter kind of rolling growth trend.”
“So two key drivers in the business are the melanoma test, or Decision DX melanoma and tissue cipher. We saw good performance in both. Modest, I would say, incremental ASP progress across both through the first half of the year.”
“Reiterating Derek's sentiment, we're proud to report excellent financial results for the second quarter of 2026.”
“On the margin side, it's a, SCC is a very efficient test for us. We don't necessarily have incremental lab space or lab technicians that aren't otherwise occupied.”
“You know, as you noted, we continue to see really strong growth there with 58% year-over-year growth. On the sequential or quarter-to-quarter trend there, you know, I think we finally have hit the penetration level where we are seeing seasonality and seeing and feeling the sense of that.”
Start not stated–present
Last confirmed April 27, 2026
Start not stated–present
Last confirmed April 8, 2026
Diagnostics & Research · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Castle Biosciences Inc (CSTL) | Chief Financial Officer | $488,800 | $880,250 |
| 2022 | Castle Biosciences Inc (CSTL) | Chief Financial Officer | $470,000 | $2,607,073 |
| 2021 | Castle Biosciences Inc (CSTL) | Chief Financial Officer | $450,000 | $2,865,351 |
| 2020 | Castle Biosciences Inc (CSTL) | Chief Financial Officer | $400,000 | $2,217,067 |
| 2019 | Castle Biosciences Inc (CSTL) | Chief Financial Officer | $327,117 | $1,498,232 |
| 2018 | Castle Biosciences Inc (CSTL) | Chief Financial Officer | $275,000 | $593,329 |
